A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

Condition: Multiple Sclerosis (MS)
Interventions: Drug: Ocrelizumab; Drug: rHuPH20
Sponsor: Hoffmann-La Roche
Active, not recruiting

Author:

Published July 16, 2022

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Lower Extremities Closed Kinetic Chain Training for People With MS

Health Information Technology System News and Healthcare Advances. Also Learn More about the Field of Health Data Scientists

Please leave this field empty

Health Data Scientist

Don’t miss these tips!

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

Evaluate New Health Applications. Be the first to decide. Your opinion matters.